US FDA warns of liver injury cases tied to Amgen's rare disease drug

The FDA identified cases of liver injury linked to Amgen's drug for a group of rare autoimmune diseases and advised clinicians to closely monitor patients and discontinue treatment if liver damage is suspected. The safety alert increases downside risk to the drug's commercial outlook and could prompt label changes, prescribing limitations, or further regulatory action. Expect near-term downside pressure on Amgen shares and heightened scrutiny from healthcare providers.

Analysis

The FDA identified cases of liver injury linked to Amgen's drug for a group of rare autoimmune diseases and advised clinicians to closely monitor patients and discontinue treatment if liver damage is suspected. The safety alert increases downside risk to the drug's commercial outlook and could prompt label changes, prescribing limitations, or further regulatory action. Expect near-term downside pressure on Amgen shares and heightened scrutiny from healthcare providers.